Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fendiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.96 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.96 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.96 |
| ▸ | CASR known ✓ | P41180 | 2/20 | 0.96 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.96 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.96 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.61 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.61 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.61 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.61 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fendiline SCHEMBL15571059 | 1.00 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| Fendiline SCHEMBL15572599 | 1.00 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| Fendiline SCHEMBL14415809 | 0.98 | OPRM1 (1.00) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| Fendiline SCHEMBL63814 | 0.98 | OPRM1 (1.00) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| Fendiline SCHEMBL5053865 | 0.98 | OPRM1 (1.00) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| Fendiline SCHEMBL14415808 | 0.98 | OPRM1 (1.00) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| SCHEMBL9660642 | 0.91 | HTR1A (0.86) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL9661761 | 0.90 | KMT2A (0.81) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| SCHEMBL9662753 | 0.89 | HTR1A (0.83) | KMT2AMEN1CYP3A4ALDH1A1HTT | |
| SCHEMBL9661837 | 0.88 | HTR1A (0.80) | KMT2AMEN1CYP3A4ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605383-B2 | Methods of treating cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-04-21 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20230338384-A1 | METHODS OF TREATING CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-10-26 | — | — | US | claimed |
| US-11766427-B2 | Repurposing compounds for the treatment of infections and for modulating the composition of the gut microbiome | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2023-09-26 | — | — | US | claimed |
| WO-2022115767-A1 | METHODS OF TREATING CANCER | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-02 | — | — | WO | claimed |
| CN-114191553-A | Medicine for resisting novel coronavirus SARS-CoV-2 and its application | 中国医学科学院病原生物学研究所 | 2022-03-18 | — | — | CN | claimed |
| CN-114191552-A | Medicine for resisting novel coronavirus SARS-CoV-2 and its application | 中国医学科学院病原生物学研究所 | 2022-03-18 | — | — | CN | claimed |
| EP-3752137-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2020-12-23 | — | — | EP | claimed |
| US-9474730-B2 | Methods and compositions for use with K-ras mediated disorders | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-10-25 | — | — | US | claimed |
| US-20130296438-A1 | METHODS AND COMPOSITIONS FOR USE WITH K-RAS MEDIATED DISORDERS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-11-07 | — | — | US | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| US-20100029654-A1 | CARDIOVASCULAR COMPOSITIONS AND USE OF THE SAME FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MOUNT SINAI SCHOOL OF MEDICINE | 2010-02-04 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| EP-2007385-A2 | CARDIOVASCULAR COMPOSITION AND USE THE SAME FOR THE TREATMENT OF ALZHEIMERS DISEASE | Mount Sinai School of Medicine (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007114948-A2 | METHODS AND COMPOSITIONS FOR INHIBITING CELL DEATH | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-10-11 | — | — | WO | claimed |
| WO-2007112288-A2 | CARDIOVASCULAR COMPOSITION AND USE THE SAME FOR THE TREATMENT OF ALZHEIMERS DISEASE | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2007-10-04 | — | — | WO | claimed |
| EP-0078820-B1 | INCLUSION COMPLEXES OF N-(1-PHENYLETHYL)-3,3-DIPHENYLPROPYLAMINE RESPECTIVELY THE HYDROCHLORIDE THEREOF WITH CYCLODEXTRIN, A PROCESS FOR THE PREPARATION OF THESE INCLUSION COMPLEXES AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THESE INCLUSION COMPLEXES | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1987-12-09 | — | — | EP | claimed |
| US-4518588-A | CORONARY DILATOR CALCIUM ANTAGONIST | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1985-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338384-A1 | METHODS OF TREATING CANCER | KRAS, TP53, HRAS | OPRM1 4628/4885HTR1A 4790/4885SLC6A2 4772/4885 |
| US-12605383-B2 | Methods of treating cancer | IL36G, IL2RA, TP53 | OPRM1 3547/4885HTR1A 4491/4885SLC6A2 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.